Distinct reward processing by subregions of the nucleus accumbens

share:

Brief intro:

  • Author: Gaowei Chen, Shishi Lai, Guo Bao, Jincan Ke, Xiaogao Meng, Shanshan Lu, Xiaocong Wu, Hua Xu, Fengyi Wu, Yu Xu, Fang Xu, Guo-Qiang Bi, Guangdun Peng, Kuikui Zhou, and Yingjie Zhu
  • Journal: Cell Reports
  • Doi: https://www.doi.org/10.1016/j.celrep.2023.112069
  • Publication Date: 2023 Feb 28

Products/Services used in the paper

Quotation shows PackGene:AAV2/8-hEF1a-ChR2-mCherry

Research Field:CNS

AAV Serotype:AAV2/8

Targeted organ:brain

Request Quote

Abstract

The nucleus accumbens (NAc) plays an important role in motivation and reward processing. Recent studies suggest that different NAc subnuclei differentially contribute to reward-related behaviors. However, how reward is encoded in individual NAc neurons remains unclear. Using in vivo single-cell resolution calcium imaging, we find diverse patterns of reward encoding in the medial and lateral shell subdivision of the NAc (NAcMed and NAcLat, respectively). Reward consumption increases NAcLat activity but decreases NAcMed activity, albeit with high variability among neurons. The heterogeneity in reward encoding could be attributed to differences in their synaptic inputs and transcriptional profiles. Specific optogenetic activation of Nts-positive neurons in the NAcLat promotes positive reinforcement, while activation of Cartpt-positive neurons in the NAcMed induces behavior aversion. Collectively, our study shows the organizational and transcriptional differences in NAc subregions and provides a framework for future dissection of NAc subregions in physiological and pathological conditions.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download